Pharvaris (PHVS) Exchange Rate Effect (2020 - 2026)
Pharvaris' (PHVS) quarterly Exchange Rate Effect came in at $4.9 million in Q1 2026, up 183.79% YoY from $1.7 million in Q1 2025, and up 5398.82% on a QoQ basis from $88541.8 in Q4 2025.
Pharvaris (PHVS) Exchange Rate Effect (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Exchange Rate Effect data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Exchange Rate Effect rose 183.79% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 306.13% YoY) and the FY2025 annual result came in at -$14.0 million, down 273.11% from the prior year.
- Exchange Rate Effect grew to $4.9 million in Q1 2026, from $88541.8 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $752.6 billion in Q3 2023 to a low of -$752.8 billion in Q2 2023.
- A 5-year average of -$13.1 million and a median of $88541.8 in 2025 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 6439040.72% in 2023, down 6196390.97% in 2023.
- Tracing PHVS's Exchange Rate Effect over 5 years: stood at -$15.6 million in 2022, then surged by 65.38% to -$5.4 million in 2023, then jumped by 299.46% to $10.8 million in 2024, then slumped by 99.18% to $88541.8 in 2025, then jumped by 5398.82% to $4.9 million in 2026.
- The last three Exchange Rate Effect figures came in at $4.9 million (Q1 2026), $88541.8 (Q4 2025), and -$37999.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | 3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.81 Mn |
| Jun 30, 2026 | 3.81 Mn |
| Mar 31, 2026 | 4.87 Mn |
| Mar 31, 2026 | 4.87 Mn |
| Dec 31, 2025 | 88,541.81 |
| Dec 31, 2025 | 88,541.81 |
| Sep 30, 2025 | -37,998.97 |
| Sep 30, 2025 | -37,998.97 |
| Jun 30, 2025 | -7.85 Mn |
| Jun 30, 2025 | -7.85 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | 10.78 Mn |
| Dec 31, 2024 | 10.78 Mn |
| Sep 30, 2024 | -6.38 Mn |
| Sep 30, 2024 | -6.38 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 627,925.79 |
| Mar 31, 2024 | 627,925.79 |